Biotia Brings Clinical Metagenomics Into Patient Care

Biotia is building infectious-disease diagnostics for the cases that refuse to behave like textbook examples. The New York health-tech company combines clinical metagenomic sequencing with AI-based analysis to identify pathogens and antimicrobial-resistance markers in difficult infections.

Co-founders Niamh O'Hara, PhD, CEO, and Christopher Mason, PhD, Global Director, developed the company from research at the Jacobs Technion-Cornell Institute at Cornell Tech. Biotia now operates a high-complexity, CLIA-certified laboratory in Long Island City and serves patients, clinicians, health systems, and researchers through diagnostic tests and pathogen-genomics software.

Biotia matters now because the company has moved beyond proving that sequencing can find more microbial information. Its harder assignment is making that information clinically useful, interpretable, accessible, and reimbursable. A new $9M financing, laboratory expansion, two live lab openings, and product work in women's health and orthopedics put that operating challenge in full view.

About Biotia

Biotia was founded in 2016 and grew from research led by O'Hara and Mason at Cornell Tech. Its mission is straightforward: give patients and providers more complete pathogen insight when standard infectious-disease testing leaves uncertainty behind.

The company works across two connected product layers. BIOTIA-ID applies metagenomic next-generation sequencing to clinical specimens. BIOTIA-DX analyzes pathogen genomic data for identification, variant tracking, and antimicrobial-resistance signals. Biotia says the BIOTIA-DX database contains more than 7,000 clinically curated microbes and can support both diagnostic workflows and hospital isolate or outbreak analysis.

That combination matters because sequencing alone is not an answer. A raw microbial readout can be broad, noisy, and difficult to interpret. The commercial product is the chain around the sequence: specimen handling, controls, curated references, classification, clinical reporting, and a result that a physician can use without becoming a bioinformatician before lunch.

The Clinical Problem Biotia Is Solving

Biotia's clearest clinical use case is the recurrent, complicated, or culture-negative urinary tract infection. Standard urine culture remains central to care, but it depends on organisms growing under selected laboratory conditions. Prior antibiotic exposure, slow-growing organisms, polymicrobial infections, or organisms outside a fixed panel can complicate that picture.

BIOTIA-ID Urine analyzes microbial genetic material and reports across 44 UTI-associated pathogens and 16 antimicrobial-resistance markers. A 2026 peer-reviewed study in Microbiology Spectrum evaluated 1,470 urine specimens and more than 14,500 analytes. After comparator adjudication, the study reported 97.2% sensitivity and 99.6% specificity.

Those numbers support the assay under the study design. They do not mean every detected organism causes disease, every treatment decision becomes obvious, or every patient's outcome improves. That distinction is the difference between useful clinical evidence and a victory lap with a lab coat.

BIOTIA-ID Urine is a laboratory-developed test performed in Biotia's CLIA-certified laboratory and approved by New York State's Clinical Laboratory Evaluation Program. It is available across all 50 states. Biotia also states clearly that the test has not been cleared or approved by the FDA.

From a Urine Test to a Diagnostic Platform

Biotia's broader ambition is visible in BIOTIA-DX. The software can analyze isolates, identify strains, characterize resistance, and help healthcare facilities investigate potential outbreaks. The company says the platform works with common short- and long-read sequencing data and supports comparisons across samples and public genomic references.

Biotia has worked with NASA's Jet Propulsion Laboratory on pipeline components and microbial samples from the International Space Station. The company also joined the Mayo Clinic Platform to strengthen BIOTIA-DX's clinical development. In orthopedics, Biotia is working with Hospital for Special Surgery on BIOTIA-ID Joint Fluid for joint infections; the current product remains research-use only.

These relationships are meaningful development signals, not shortcuts to a commercial conclusion. Biotia has not disclosed revenue, deployment volume, or customer economics from the collaborations. Each new specimen type still needs its own evidence, workflow, regulatory path, and clinician trust.

Leadership, Capital, and the Next Operating Test

O'Hara and Mason anchor a leadership group spanning medicine, laboratory science, software, and finance. Dorottya Nagy-Szakal, MD, PhD, is Chief Medical Officer; Mara Couto-Rodriguez, MS, is Chief Scientific Officer; David Danko, PhD, is Chief Technology Officer; John Lomoro, CPA, is Chief Financial Officer; and Caitlin Otto, PhD, is Clinical Laboratory Director.

The team has financed Biotia in stages. The company announced a $2.4M seed round in 2019 and an oversubscribed $8M Series A led by OCA Ventures in 2022. In October 2026, Biotia announced a new oversubscribed $9M financing. It did not disclose a round label, lead investor, valuation, security, or detailed terms.

The company said the new capital will scale the Long Island City laboratory, expand diagnostics in women's health, pursue reimbursement and clinician access, and advance orthopedic testing. That plan is less glamorous than pretending software makes healthcare friction disappear. It is also more credible. A diagnostic company has to make the laboratory, evidence, ordering pathway, report, payment process, and clinical decision move together.

Culture and the Hiring Signal

Biotia's stated values emphasize patient belief, scientific integrity, clinical clarity, purposeful innovation, and equitable access. The first two belong together. Patients with persistent symptoms want to be heard; clinicians also need evidence strong enough to separate a meaningful finding from additional microbial noise.

The company's careers page reflects the practical work behind that promise. At the time of review, Biotia listed two live, in-person Long Island City roles: Clinical Laboratory Technologist and part-time Specimen Accessioner. Those are not decorative startup hires. They sit where specimens are received, checked, processed, documented, and translated into a regulated laboratory workflow.

The hiring signal is narrow but useful. Biotia is adding operating capacity around the clinical laboratory while fresh capital supports expansion. It does not prove broad headcount growth, and a separate supervising-technologist role was marked closed. Candidates should use the live careers page as the current source of truth.

What Biotia Signals for Clinical Diagnostics

Clinical metagenomics has spent years demonstrating that it can see more. The next market question is whether companies can turn that wider field of view into repeatable care without confusing detection with diagnosis or novelty with adoption.

Biotia has assembled many of the pieces: a regulated laboratory, a nationwide urine test, peer-reviewed validation, pathogen-genomics software, institutional collaborations, a test-specific billing code, and financing for reimbursement and new clinical areas. The remaining work is coordination. Clinicians need clear indications. Patients need access. Payers need evidence. New assays need validation. Every handoff can slow the product or make it more durable.

That is why Biotia is worth watching. The company is not merely asking whether sequencing can find a pathogen. It is trying to build the operating system that gets a defensible answer from the sample to the person who has to act on it.